 |
|
"A model System for Validation of PET Radiopharmaceuticals: Focusing on Tumor Microenvironment"
written by Anatole A. Klyosov, Igor L. Rozhanskii,
published by International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, Vol.2 No.1, 2013
has been cited by the following article(s)：
-
[1] Combined Injection of< sup> 18 F-Fluorodeoxyglucose and 3′-Deoxy-3′-[< sup> 18 F] fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study
Translational oncology 2013[2] The Usefulness of Combined Diagnostic CT and 99mTc-Octreotide Somatostatin Receptor SPECT/CT Imaging on Pulmonary Nodule Characterization in Patients
Cancer Biotherapy and Radiopharmaceuticals 2013[3] Preclinical Visualization of Hypoxia, Proliferation and Glucose Metabolism in Non-small Cell Lung Cancer and Its Metastasis
Abdomen and Thoracic Imaging 2014[4] 18 F-Fluorodeoxyglucose Uptake and Tumor Hypoxia: Revisit 18 F-Fluorodeoxyglucose in Oncology Application
Translational oncology 2014[5] 18F-fluorodeoxyglucose uptake and tumor hypoxia: Revisit 18F-fluorodeoxyglucose in oncology application
Translational Oncology 2014[6] Combined injection of 18F-fluorodeoxyglucose and 3′-deoxy-3′-[18F] fluorothymidine PET achieves more complete identification of viable lung cancer cells in mice …
Translational Oncology 2013[7] Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination
PLOS ONE 2018 - No relevant information.